Abstracts

390 – Immune-Related AEs After Low-Dose, Finite-Duration Budigalimab ± Trosunilimab in PWH

Background Budigalimab and trosunilimab, recombinant IgG1 monoclonal antibodies that bind cell-surface PD-1 receptor and α4β7 integrin, respectively, are being studied as a potential strategy for immune-mediated control of HIV. In oncology indications, higher doses of budigalimab (250-500mg) are associated with immune-related adverse events (irAEs) in ~40% of patients (5% Grade [Gr]≥3). However, the safety profile of…

795 – Efavirenz Pharmacokinetics in Pregnancy and Postpartum With and Without First-Line TB Drugs

Background Efavirenz (EFV) pharmacokinetics (PK) may be influenced by both pregnancy-related physiological changes and concurrent treatment for drug-sensitive tuberculosis (DS-TB) in pregnant women living with HIV (PWLHIV) with TB disease. As EFV might be preferred over dolutegravir to avoid double dosing during DS-TB treatment, more EFV PK data in PWLHIV on DS-TB treatment are needed, as only limited…

1007 – HPV Genotypes and Risk Factors in MSM Without HIV: Informing Prevention Within PrEP Programs

Background Men who have sex with men (MSM) using HIV-pre-exposure prophylaxis (PrEP) show increased vulnerability to human papillomavirus (HPV)-related cancers. Despite this, comprehensive clinical guidelines for this population remain absent. Identifying specific risk factors is essential for sexual health centers to optimize care among MSM using PrEP. This study aims to collect HPV-related data in…

557 – Genetically Inferred Patterns of Transmitted HIV Pretreatment Resistance in Southern Uganda

Background During HIV antiretroviral therapy scale-up there has been an increase in pre-treatment non-nucleoside reverse transcriptase inhibitor resistance observed among individuals initiating antiretroviral therapy. These data provide limited insights into how resistance spreads within communities. Population-level data of pre-treatment resistance are exceedingly rare, particularly from sub-Saharan Africa.  Methods We analyzed data from the population-based Rakai…

1045 – DoxyPEP Counseling and Use Among PrEP Users: Cross-Sectional Survey in the Italian PrIDE Cohort

Background Doxycycline postexposure prophylaxis (DoxyPEP) patterns of counseling and uptake among European PrEP users are scarce. In Italy, no official DoxyPEP guidelines are available. Aims are to assess the prevalence of DoxyPEP counseling and use in Italy and to identify associated factors to guide equitable scale-up. Methods This is a cross-sectional analysis of PrEP users…

328 – Accelerated Longitudinal Decline of Intact Proviruses During ART in the LoViRet Cohort

Background Among people living with HIV (PLWH) receiving long-term antiretroviral therapy (LT-ART), the frequency of intact HIV-1 proviruses varies considerably, likely reflecting differences in immune pressure on the reservoir cell pool. Characterizing reservoir dynamics in individuals with exceptionally low reservoir under ART may provide critical insights for reservoir reduction and HIV cure strategies. In this…

347 – High-Throughput HIV-1 Reservoir Mapping: Intactness, Drug Resistance, and Immune Therapy Predictions

Background HIV-PULSE (HIV Proviral Unique molecular identifier mediated Long-read Sequencing) is a novel and cost-effective assay for near full-length (NFL) HIV-1 proviral sequencing. A detailed understanding of the viral reservoir is crucial for advancing curative efforts. This study explores the potential of HIV-PULSE to profile the HIV-1 reservoir in a high-throughput manner by analyzing key…

351 – CRISPR Screening Reveals Mitochondrial Dysfunction as a Novel Mechanism of HIV Reactivation

Background CRISPR screening is a powerful approach to study HIV. The dual reporter HIVGKO enables the identification of HIV latently infected cells through the expression of two fluorescent proteins, GFP and mKO2. Here, we performed CRISPR screening using HIVGKO to identify host genes regulating HIV latency. Methods We generated Jurkat GKO Latent (JGL) cells by infecting Jurkat…